Vaxart, Immunovaccine, Mayo Clinic jump onto Zika vaccine bandwagon
Widening the field further, Vaxart, Immunovaccine and Mayo Clinic are joining a slew of biotechs and pharmas either exploring or embarking on Zika vaccine development.
U.K. rejects petition demanding meningitis B vaccine for all children
Sanofi's Dengvaxia is set for a wide rollout in the Philippines, making the endemic nation the first to implement an immunization campaign utilizing the dengue fever vaccine. Read more >>
Philippines' immunization program for Sanofi's Dengvaxia set to start in April
Sanofi's Dengvaxia is set for a wide rollout in the Philippines, making the endemic nation the first to implement an immunization campaign utilizing the dengue fever vaccine. Read more >>
TOP HEADLINES
Featured Story
Sanofi digs into details on hastened Zika effort
Just last month, Sanofi became the first Big Pharma player to enter the Zika vaccine R&D space as its peers calculated their responses and weighed their options. Now, the French pharma is taking it a step further, outlining its plans to devote dozens of scientists to the field in a move aimed at expediting its vaccine development.
Duke, NIAID track HIV evolution with eyes on creating a vaccine
A team led by the Duke Human Vaccine Institute and the National Institute of Allergy and Infectious Diseases has tracked the evolution of HIV and the body's corresponding immune response, hoping now to turn the knowledge gained into an experimental vaccine.
South Korea's Green Cross to supply Americas with flu vaccine in $32M deal
South Korea's Green Cross announced a $32 million deal on Wednesday to supply its flu vaccines to the Pan American Health Organization, the WHO's regional office in the Americas.
U.S. Army, GSK's P. vivax malaria vaccine fails to protect in early trial
A vaccine developed in collaboration between GlaxoSmithKline and the U.S. Army failed to protect subjects in an early trial against the world's most prevalent malaria parasite. Researchers will press forward, however, saying the knowledge gained may assist future development.
New South Korean study could help direct MERS vaccine development
Several players are working on vaccines for Middle East respiratory syndrome (MERS), including the NIH and tandem GeneOne and Inovio, both of which had successful animal trials for their candidates. Now, a new study out of South Korea--showing that the MERS virus mutated during the outbreak--could help vaccine developers pinpoint their target on the surface of the MERS virus.
Novavax explores Zika vaccine R&D effort as virus continues to spread
Vaccine companies and research organizations worldwide continue to race against Zika, with a new entrant emerging in Novavax. The biotech announced it's conducting preliminary Zika research in a week that saw several other developments in the field.
From Our Sister Sites
- FierceBiotech
- FierceBiotechIT
- FierceBiotechResearch
- FierceDrugDelivery
- FierceMedicalDevices
- FierceVaccines
- FiercePharma
- FiercePharmaAsia
- FiercePharmaManufacturing
- FierceCRO
- FierceDiagnostics
- FiercePharmaMarketing
- FierceAnimalHealth
- More Fierce Network sites
Activist investor and one-time Valeant enthusiast Bill Ackman is tired of waiting for Valeant's plunging stock price to turn itself around.
It seems to be two steps forward, one step back for India's Lupin in its efforts to build its business in the U.S. A week after the drugmaker closed a deal that gets it its first U.S. manufacturing facility, another of its plants in India has been found lacking by the FDA.
POPULAR COMMENT THREADS